Table 2 Multivariate analyses of DFS and OS in EGFR-mutant NSCLC patients receiving complete resection.

From: Outcomes of adjuvant epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment for EGFR-mutant non-small-cell lung cancer: a propensity-score analysis

Resection type

DFS

OS

HR(95%CI)

P

HR(95%CI)

P

Adjuvant EGFR TKIs (Yes vs. No)

0.51(0.27–0.97)

0.04

0.78(0.44–1.41)

0.41

Pathologic stage

 

<0.001

 

<0.001

I

Reference

 

Reference

 

II

1.64(0.89–3.02)

0.11

1.47(0.74–2.92)

0.27

III

3.04(1.72–5.37)

<0.001

3.63(1.95–6.75)

<0.001

Adjuvant chemotherapy (Yes vs. No)

0.67(0.43–1.06)

0.07

0.55(0.33–0.91)

0.02

  1. Abbreviations: DFS, disease-free survival; OS, overall survival; HR, hazard ratio; 95% CI, 95% confidence interval.
Back to article page